The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for UK pharma major GlaxoSmithKline’s (LSE: GSK) malaria candidate vaccine Mosquirix, also known as RTS,S, in children aged six weeks to 17 months.
Following this decision, the World Health Organization (WHO) will now formulate a policy recommendation on use of the vaccine in national immunization programs once approved by national regulatory authorities.
Won’t be a money spinner for GSK
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze